Clinical Trials Logo

Clinical Trial Summary

This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2. Each subgroup will comprise of two treatment arms.


Clinical Trial Description

Subjects willing to participate in the study and fulfilling all eligibility criteria will receive either oral therapy (subgroup 1) or IV therapy (subgroup 2). The investigator can initiate treatment with either oral or IV therapy based on clinical judgement i.e subjects who require IV therapy (like subjects with severe ABSSSI or where oral administration is not feasible). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03405064
Study type Interventional
Source Wockhardt
Contact
Status Completed
Phase Phase 3
Start date August 25, 2017
Completion date November 30, 2018

See also
  Status Clinical Trial Phase
Terminated NCT01734694 - Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Phase 4
Completed NCT02961764 - Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Phase 4
Completed NCT02570490 - Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT00949130 - Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Phase 2
Completed NCT03176134 - A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) Phase 3
Completed NCT03137173 - Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections Phase 3